Tag: Pharmaceuticals
Firms guide Fosun Pharma’s option agreement with AriBio
HSF, Kewei and Goodwin advise Fosun Pharma on USD240 million AriBio Alzheimer’s drug agreement
Simpson Thacher assists on USD711m global equity offering
Simpson Thacher advises Japan’s Sumitomo Pharma on its USD711m international share offering
Allen & Gledhill launches two new practices in Singapore
Allen & Gledhill establishes two new practices – technology disputes, and healthcare, life sciences and pharmaceuticals
Metis IPO is world’s first AI driven nano-delivery firm listing
Metis TechBio debuts on the HKEX on 13 May, raising HKD2.1 billion in the world’s first listing of an AI driven nano-delivery platform company
Firms act on medtech maker Cofoe Medical’s HKD1.06bn IPO
Cofoe Medical Technology lists on the HKEX main board becoming the first home medical equipment maker to achieve a dual listing
Trends in biologic patent litigation
Biosimilars, biologics and patents: High Court decisions reshape claim mapping, discovery and injunctions in India
‘Family of marks’ doctrine in India
Family of marks doctrine under Indian law: Judicial origins, recognition criteria and infringement implications explained
Pharmaceuticals partner returns to Hogan Lovells in Washington
Hogan Lovells welcomes back Tao Xin as a partner in Washington, boosting its global pharmaceuticals and biotechnology practice
Firms steer Everstone’s USD270m Apothecon investment
Firms counsel on?Everstone Capital’s USD270 million investment?in?drugmaker?Apothecon?Group?
Jia Yuan adds capital markets partner in Hong Kong
Jia Yuan Law Offices has hired Echo Shen as a partner at its Hong Kong office
Grandway adds two capital markets partners
Grandway has recruited partners Zhang Liu and Zhang Cheng, strengthening its securities and capital markets practice
Harnessing capital market waves
Market reforms, investor activity and fundraising trends highlight the investment ecosystems in Hong Kong and Taiwan
Firms advise on GSK’s USD2.2bn RAPT buy, accesses China drug
British pharmaceutical giant GSK has entered an agreement to acquire US-based clinical-stage biopharmaceutical company RAPT Therapeutics for around USD2.2 billion
Firms advise on RemeGen’s USD5.6bn AbbVie licensing deal
Freshfields and Global Law Office have advised Chinese biotech RemeGen on an exclusive licensing agreement with AbbVie
The A-List 2025-26: Growth Drivers
Growth Drivers: We highlight leading Chinese and international lawyers who excel across legal and business sectors
Firms advise on Insilico Medicine’s HKD2.28bn HKEX IPO
AI drug discovery firm Insilico Medicine listed on the HKEX main board on 30 December 2025
AstraZeneca recruits former Merck executive legal director
AstraZeneca appoints former MSD legal director James Yuan as head of Asia-Pacific compliance investigations
Firms advise on WuXi AppTec’s China clinical research sale
WuXi AppTec has sold its China clinical research services business to Hillhouse Investment
Opportunities in Japan’s regenerative medicine, gene therapy markets
Japan emerges as a hub for regenerative medicine, with opportunities for foreign companies amid strict local regulations
Rouse acquires Australian IP firm in Asia-Pacific expansion
UK-based Rouse boosts regional presence with Wrays, a 100-year-old IP firm in Australia and New Zealand
Firms act on Hengrui-GSK USD12.5bn drug development deal
Jiangsu Hengrui and GSK reached a USD12.5bn deal, with Cooley, Davis Polk and Han Kun advising
In the fast lane
The India-UAE CEPA has set a benchmark for modern trade agreements, yielding benefits in many sectors
Global standards, local hurdles: 含羞草社区 product testing framework
含羞草社区 outdated product testing rules raise compliance costs and delay market access, calling for urgent reform and global alignment
FDI in manufacturing, Make in India: A decade in review
India attracted USD165.1 billion in FDI to manufacturing over 10 years, boosted by Make in India and related reforms
Record China pharma monopoly fine a deterrent, says expert
China issues record pharma fine, targeting firms and individual for monopoly violations
Shujath Bin Ali in new role as Fourth Partner Energy’s CLO
Shujath Bin Ali becomes chief legal officer at Fourth Partner Energy, a top renewable energy platform in India
Akshay Kishore joins Duane Morris & Selvam as director
Akshay Kishore has joined Duane Morris & Selvam as a director while Mark Ng will be joining him as a senior associate
Isshiki boosts IP with ex-Novartis Japan GC’s partner hire
Isshiki & Partners has strengthened its IP practice with the partner hire of Hiromi Furushima
Hengrui raises HKD9.8bn in HK’s largest pharma IPO in 5 years
Hengrui raises HKD9.8bn in Hong Kong's largest pharma IPO in five years
Japan’s path for drug transfers
Japan’s pharma market demands careful regulatory and approval transfer compliance
Top Japanese firms steer USD1.1bn Japan pharma takeover
Nagashima Ohno advises JT’s Torii on JPY160b takeover bid by Shionogi, which is counselled by Nishimura & Asahi
Healthcare and life science regulation in Japan
Japan is easing restrictions on medical data under two key laws as it focuses on promoting the use of this information
Wong & Partners hires IP specialist from Malaysia rival
Wong & Partners has hired Celia Cheah as IP partner; she brings 20+ years of expertise from Christopher & Lee Ong
Life sciences sector in Russia: Regulatory landscape for 2025
The life sciences sector in Russia stays stable with local production incentives and EEU regulatory unity
Tempus Law, AZB act on PAG’s USD200m packaging acquisition
AZB & Partners and Tempus Law Associates advised on PAG’s USD200 million majority stake acquisition in Pravesha Industries
A comparison of developments in healthtech
South Korea boosts drug development; Russia tackles telemedicine and data protection
Mice not meek over morality and amendment
Section 3(b) of the Indian Patents Act, 1970, bars patents for inventions contrary to morality or harmful to life
Infringing pharmaceutical IP has legal side effects
In Zuventus Healthcare Limited v Zaventis Health Care Private Limited, the plaintiff sought an urgent permanent injunction from Delhi High Court without notifying the defendant
Skadden, Latham & Watkins steer USD1.12bn biotech sale
Skadden and Latham & Watkins are advising Otsuka Pharmaceutical on its USD1.12 billion acquisition of Jnana Therapeutics
Simpson, Nishimura act on USD2.1bn Japan pharma buyout
Simpson Thacher & Bartlett and Nishimura & Asahi are advising on the USD2.1 billion acquisition of Alinamin
Under the microscope
A comparison of evolving legal frameworks that are helping to shape the massive life sciences industries in China and India
Navigating China’s new protections for life science patents
China’s 2021 Patent Law overhauled life sciences protection with US-style patent linkage, term extension (PTE), and term adjustment (PTA)
Delicate balance of life sciences laws in India
India's life sciences laws regulate medicines, devices, biotech, and healthcare, ensuring quality, efficacy, safety, and consumer protection
Greenberg, Goodwin act on USD2.4bn Deciphera-ONO biotech deal
Goodwin Procter and Greenberg Traurig have assisted on a USD2.4 billion merger between American biotechnology enterprise Deciphera with ONO
Investors ride wave of cross-border biomedical acquisitions
Amid the cool capital markets climate, the recent surge in billion-dollar M&A deals involving overseas biomedical companies
Quartet guides HKD8.79bn privatisation bid for SciClone
Kirkland & Ellis, Clifford Chance, Sullivan & Cromwell and Slaughter and May advise on Silver Pegasus Investment's HKD8.79 billion take-private of SciClone Pharmaceuticals in Hong Kong
Trilegal acts for JB Pharmaceuticals on Novartis acquisition
Trilegal advised JB Pharmaceuticals in its acquisition of a portfolio of specific ophthalmology brands from Novartis for INR10.9 billion
A comparison of healthtech regulatory issues in North Asia
Drug pricing and reimbursement top the agenda in South Korea, while Japan is exploring the impact of digital technology on medical information
BJContinent achieves first reverse US takeover under new rules
Gibson Dunn, Orrick, and DeHeng facilitate BJContinent's historic reverse US takeover under new rule
Patent litigation expert Timothy Bickham joins Dentons
Dentons welcomes partner Timothy Bickham to the Washington DC Office, who will also be head of Dentons China’s IP litigation team to improve the firm’s patent litigation services
JSA advises Torreya on acquisition by Stifel
JSA advised Torreya Holdings in the 100% acquisition of Torreya Partners by Stifel Financial Corp for an undisclosed amount
How can pharmas amid VBP reform ‘make elephants dance’?
Volume-based procurement (VBP) of drugs and medical supplies has become the new normal in China’s medical sector
Khaitan advises Eris on USD42m buy of Glenmark trademarks
Khaitan & Co assisted Eris Oaknet Healthcare in a USD42 million deal to acquire nine dermatology trademarks from Glenmark Pharmaceuticals
Fangda Partners beefs up biopharmacy, aircraft leasing practices
Fangda Partners has hired Shanghai-based Henry He and Guangzhou-based Judy Tan as partners to grow the firm’s biopharmaceutical and aircraft leasing business
Anti-bribery laws, industry codes in Japan’s healthcare sector
In this article, they explain from first-hand experience major legal and compliance risks for healthcare companies operating in Japan




























































































































